194 results
8-K
EX-99.1
JAZZ
Jazz Pharmaceuticals plc
1 May 24
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results
4:06pm
offset by lower neuroscience revenues. Total neuroscience revenue, including high-sodium oxybate AG royalty revenue, of $630.9 million decreased in 1Q24 … -sodium oxybate competition and changes to formulary coverage, partially offset by increased royalty revenue received on net sales of high-sodium oxybate
8-K
EX-99.1
JAZZ
Jazz Pharmaceuticals plc
28 Feb 24
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results
4:06pm
, and royalties on net sales of authorized generics of Xyrem® offset by a continued decline in net sales of Xyrem.
1 Total Sleep revenue includes … and $728.9 million in 4Q23, was broadly in line with the same periods in 2022 and included increased Xywav and Epidiolex/Epidyolex net product sales, offset
8-K
EX-10.1
dvqwaqubxjxm
25 Jan 24
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-99.1
xyqgz
8 Nov 23
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:07pm
8-K
EX-99.1
8erglqfrr
9 Aug 23
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
4:07pm
8-K
EX-99.1
nooscqfmdq8zr6rxo9
10 May 23
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance
4:08pm
8-K
EX-99.1
jkra5h6ojr4q s6n
9 Nov 22
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
4:07pm
8-K
EX-99.1
glglny wpjr1h3lqe
3 Aug 22
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
4:07pm
8-K
EX-99.1
pzq9zy8uqr xm
4 May 22
Jazz Pharmaceuticals Announces First Quarter 2022
4:13pm